Andrew Matzkin

@MatzkinHealth

Health-tech strategist: Digital Health, RWE, Precision Medicine, Analytics/Informatics. Partner at Health Advances

San Francisco, CA
Vrijeme pridruživanja: kolovoz 2013.

Tweetovi

Blokirali ste korisnika/cu @MatzkinHealth

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MatzkinHealth

  1. Prikvačeni tweet
    11. svi 2018.

    I'm excited to share some insights on adoption strategy for digital health from our recent panel featuring executives from and . Special thanks to iRhythm for hosting and to the 75+ who attended.

    Poništi
  2. proslijedio/la je Tweet
    3. velj

    I enjoyed reading this article about companies that are moving into the space of A blood test to screen for cancer They have an uphill battle that I fear they do not yet fully recognize [Thread]

    Prikaži ovu nit
    Poništi
  3. 30. sij

    Wow that's a lot of $$$! Patient-centric digitally-enabled pharmacy models are sorely needed, especially in specialty pharmacy. Exciting development for a promising company. (Congrats, !)

    Poništi
  4. 30. sij

    This pivot highlights continued HCP resistance to clinical decision support (CDS). Even if admins decide they need it for quality and/or $$ reasons, front-line docs don't want to use it. So, instead, Syapse pivots to selling data services to drug co's, like Flatiron, Tempus, Cota

    Poništi
  5. proslijedio/la je Tweet
    29. sij

    Must-read, describing experiences of as he tries to get own hlth records (unsuccessfully), & has his meds misrecorded- i.e. the usual. He also lambasts anti-interop of certain EHR co's. Resonates w/recent

    Poništi
  6. proslijedio/la je Tweet
    28. sij

    Leadership News: Seasoned life sciences executive, Holger Müller, joins as a Vice President! Holger will add to HA’s expanding practice w/ a principal focus on European clients & those interested in European markets – learn more:

    Poništi
  7. proslijedio/la je Tweet
    27. sij

    Do you think "Hey, Epic!" is the first step from a big EHR (with and @mmodal) enabling true competition for scribes, in a way that and have been doing already? Or just a basic voice gimmick?

    Poništi
  8. 24. sij

    Poll time: 1 - EHRs are locked down. Hard for patients to access and for HCPs to share. Tech co's have no access. Privacy is 100%. 2- Health data flows freely. Easy ptnt access and HCP sharing. Tech co's get lots of data, some of it identifiable. Sometimes data becomes public.

    Poništi
  9. 24. sij

    Verily confirms that the Verily / iRhythm AF collaboration will be based on using Study Watch + Zio for continuous monitoring to enable screening, Dx, and patient monitoring in AF. Imagine this eventually becoming part of an -like model for CV disease... cc

    Tweet je nedostupan.
    Poništi
  10. 23. sij

    I can't get over the EPIC/Faulkner letter. Just outrageous to use fake concern for patients as a fig leaf for a position that is so obviously about self-interest. Reminds me of state medical boards fighting telemedicine. At least be better at faking that you care about patients.

    Poništi
  11. proslijedio/la je Tweet
    22. sij

    SCOOP: Verily Study Watch picks up new 510(k) for irregular pulse monitoring . Well done .

    Poništi
  12. proslijedio/la je Tweet

    This is a great article about how difficult it is to run trials/assess digital therapeutics companies, esp when it comes to trial design Key difficulty is designing a sham arm similar enough to be compared, but not enough to trigger the same effect

    Prikaži ovu nit
    Poništi
  13. 21. sij

    Can't say I ever expected to be quoted in FT talking about sensor-enabled toilet seats, but here we are. This article is a comprehensive and thoughtful look at Alphabet's future in healthcare, including both Google Health and Verily.

    Poništi
  14. 17. sij
    Prikaži ovu nit
    Poništi
  15. 15. sij

    Paging for perspective on what this could mean for federal policy and for DTx overall...

    Prikaži ovu nit
    Poništi
  16. 15. sij

    Big news for digital therapeutics (DTx)? Buried inside ONC's new Federal HIT Strategic Plan: "Advance use of evidence-based DTx as treatment options... to prevent, manage, and treat conditions through smartphones, tablets, and other personal devices."

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    15. sij

    My colleague Anastasios Pappas writes about the evolving clinical and economic evidence requirements for digital health technology in the UK.

    Poništi
  18. proslijedio/la je Tweet

    News: I talked to the CEO of struggling Proteus Digital Health to get an update on the situation there: — a codev deal with Otsuka is ending — unspecified number of layoffs — pivot to cancer/infectious diseases, away from mental illness/cardio

    Poništi
  19. proslijedio/la je Tweet
    9. sij

    Nice interview with colleagues Sheela Hegde and Leslie DeVos

    Poništi
  20. proslijedio/la je Tweet
    7. sij
    Poništi
  21. proslijedio/la je Tweet
    17. pro 2019.

    "Overcoming barriers to scale in digital therapeutics" A presentation i gave a few weeks ago at the Clinically Validated DTx Conference in Boston. Let me know what you agree or disagree with!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·